EASTONBIOPHARMACEUTICALS(SH:688513) Zheng Quan Zhi Xing·2025-08-18 11:13Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced a two-year extension for the investment period of its "Drug Clinical Research Project" due to the actual progress of the project and to align with the company's long-term development strategy [1][4]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at a price of RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement has been signed with the sponsoring institution and the bank [1]. Investment Project Details - The company has adjusted the investment allocation for its fundraising projects, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary, Shod Pharmaceutical [2][3]. - The total investment for the "Drug Clinical Research Project" is RMB 11,400.00 million, with RMB 7,384.91 million already spent, indicating a progress rate of 64.78% [3]. Project Delay Specifics - The investment deadline for the "Drug Clinical Research Project" has been extended from September 2, 2025, to August 31, 2027, to accommodate additional clinical trials required for the project [3][4]. - The delay is attributed to the need for further clinical trials for the drug "Uroglitazone" to meet submission requirements for market approval [3][4]. Impact of Delay - The extension of the investment period is a prudent decision based on the project's actual implementation status and will not adversely affect the company's normal operations or the project's overall objectives [4][5]. - The board and supervisory committee have both approved the delay, confirming that it does not involve changes to the project's total investment, purpose, or scale [4][5].